The HALP score as a prognostic factor in metastatic biliary cancer

Clinical and Translational Oncology Pub Date : 2024-09-13 DOI:10.1007/s12094-024-03702-2

İsmet Seven, İrfan Karahan, Fahriye Tuğba Köş, Doğan Bayram, Serhat Sekmek, Selin Aktürk Esen

{"title":"The HALP score as a prognostic factor in metastatic biliary cancer","authors":"İsmet Seven, İrfan Karahan, Fahriye Tuğba Köş, Doğan Bayram, Serhat Sekmek, Selin Aktürk Esen","doi":"10.1007/s12094-024-03702-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Biliary tract cancers are serious diseases and new biomarkers may be useful for the optimal management and prediction of these cases. This study aimed to evaluate the prognostic significance of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score, a novel composite marker, in patients with metastatic biliary tract cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Patients with biliary tract cancers were analyzed retrospectively. Laboratory values, patient and disease characteristics, and survival rates were evaluated. The diagnostic impact of the HALP score was assessed with regression analyses.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The study included 106 individuals with metastatic biliary tract cancer. Based on the median HALP score, ≥ 2.22 was considered a high score and < 2.22 was considered low. The overall average survival time was found to be 11.4 months. Patients with low HALP scores had median overall survival of 9.5 months, while those with high HALP scores had median overall survival of 15.9 months. In multivariate analysis, Eastern Cooperative Oncology Group performance status, CA19-9 level, and HALP score remained significant predictors of overall survival.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The HALP score appears to be a useful prognostic marker in patients with metastatic biliary tract cancer.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03702-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Biliary tract cancers are serious diseases and new biomarkers may be useful for the optimal management and prediction of these cases. This study aimed to evaluate the prognostic significance of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score, a novel composite marker, in patients with metastatic biliary tract cancer.

Methods

Patients with biliary tract cancers were analyzed retrospectively. Laboratory values, patient and disease characteristics, and survival rates were evaluated. The diagnostic impact of the HALP score was assessed with regression analyses.

Results

The study included 106 individuals with metastatic biliary tract cancer. Based on the median HALP score, ≥ 2.22 was considered a high score and < 2.22 was considered low. The overall average survival time was found to be 11.4 months. Patients with low HALP scores had median overall survival of 9.5 months, while those with high HALP scores had median overall survival of 15.9 months. In multivariate analysis, Eastern Cooperative Oncology Group performance status, CA19-9 level, and HALP score remained significant predictors of overall survival.

Conclusion

The HALP score appears to be a useful prognostic marker in patients with metastatic biliary tract cancer.

Abstract Image

查看原文本刊更多论文

作为转移性胆道癌预后因素的 HALP 评分

背景胆道癌是一种严重的疾病，新的生物标记物可能有助于这些病例的优化管理和预测。本研究旨在评估血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分这一新型复合标记物在转移性胆道癌患者中的预后意义。方法对胆道癌患者进行回顾性分析，评估实验室值、患者和疾病特征以及生存率。结果该研究纳入了106名转移性胆道癌患者。根据 HALP 评分的中位数，≥ 2.22 为高分，< 2.22 为低分。总平均生存时间为 11.4 个月。HALP评分低的患者中位总生存期为9.5个月，而HALP评分高的患者中位总生存期为15.9个月。在多变量分析中，东部合作肿瘤学组表现状态、CA19-9水平和HALP评分仍是总生存期的重要预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Oncology

自引率

0.00%

发文量